uxr102

Ulrich Rodeck, MD

Contact Dr. Rodeck

233 South 10th Street
Philadelphia, PA 19107

(215) 503-5622

Research and Clinical Interests

Regulation of epithelial cell fate by the epidermal growth factor receptor and associated signal transduction events; molecular mechanisms leading to adverse events of cancer therapy; adverse event reduction by developing drugs targeted to disease sites; zebrafish as an in vivo model system to investigate whole organism genotoxic stress responses.

My research interests revolve around signal transduction pathways regulating epithelial cell death and survival. Specifically, I am interested in coordinated signaling by receptor tyrosine kinases and integrins as it relates to the inappropriate survival of tumor cells. In these studies, we frequently use an EGFR antagonistic monoclonal antibody originally developed at the Wistar Institute (Rodeck et al. Cancer Res., 47:3692-6, 1987) and currently in phase II clinical trials in epithelial neoplasms (EMD59000; EMD72000). A second line of investigation focuses on molecular determinants of stress response pathways in vertebrate organisms. This work is done largely in zebrafish embryos to account or microenvironmental and tissue-specific effects. The goal of these studies is to identify targets for therapeutic intervention in cancer and inflammatory diseases.